February 23, 2016 Waisman Biomanufacturing and Agilis Biotherapeutics, LLC, recently announced an exclusive partnership agreement for the production AGIL-FA, a novel gene therapy product for the treatment of Friedreich’s ataxia (FA). FA is an inherited …
Waisman Biomanufacturing
An Update from the United States National Heart, Lung, and Blood Institute-funded Production Assistance for Cellular Therapies (PACT) Program: A Decade of Cell Therapy
Introduction Recognizing the emerging field of therapeutic cell-based treatments for a growing number of diseases, including the field of regenerative medicine, the National Heart, Lung, and Blood Institute (NHLBI) held a workshop in 2002, where …
Waisman Biomanufacturing plays key role in prostate cancer vaccine development
A spinoff business launched by a University of Wisconsin-Madison cancer researcher is attempting to harness the human immune system to fight prostate cancer.
Biomanufacturing center takes central role in developing stem-cell therapies
David Tenenbaum – University Communications Developing a new drug takes enormous amounts of time, money and skill, but the bar is even higher for a promising stem-cell therapy. Many types of cells derived from these …
Waisman Biomanufacturing partners with Stratatech to develop skin substitute
The grant will fund development work that will focus on the efficacy of a genetically modified living human skin substitute called ExpressGraftEnhance tissue in the prevention and disruption of biofilms. A biofilm is a community of bacteria growing in a matrix that adheres to a surface.
Federal grant funds production of stem cells for clinical trials
The long struggle to move the most versatile stem cells from the laboratory to the clinic got another boost with an $8.8 million contract award to the Waisman Clinical Biomanufacturing Facility at the University of Wisconsin-Madison.
First cGMP Feeder-Independent Pluripotent Stem Cell Banks Released for Distribution
WiCell Research Institute and Waisman Clinical Biomanufacturing Facility offer new stem cell banks to support translational research through clinical applications The WiCell™ Research Institute and the Waisman Clinical Biomanufacturing Facility (WCBF) announced today the …
Stem-cell bank tests, stores, distributes
Some of Madison’s most precious assets are deep-frozen in vials at University Research Park. The National Stem Cell Bank, the country’s only official repository of human embryonic stem cells, is housed at the WiCell Research Institute, a nonprofit organization affiliated with UW-Madison.
Stem Cells In Action
Two years after the National Institutes of Health created the National Stem Cell Bank, managers say the bank is starting to fulfill its mission: gathering the cells in one place, controlling their quality and shipping them to scientists at low cost.
Waisman Clinical BioManufacturing Facility to produce pre-flu vaccine
CytoDyn, Inc. has selected the Waisman Clinical BioManufacturing Facility at the University of Wisconsin at Madison to manufacture the Company’s DNA-based pre-flu vaccine. CytoDyn’s pre-flu vaccine provides an alternative approach to immunization that could make …